About BioCardia

We are a clinical-stage regenerative medicine company.

Our Mission: To bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Our Pipeline: Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia.

Our second therapeutic candidate is the investigational CardiALLO™  Cell Therapy System, an allogeneic culture expanded "off the shelf" cell therapy derived from donor bone marrow cells that have been identified to meet specified criteria. This therapy has the potential to be advanced for many clinical indications including heart failure.



News

28 Oct

Cardiology Today

Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
Read More
11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More
16 Apr

Saint Joseph Mercy

St. Joseph Mercy Ann Arbor to perform clinical trial using stem cells to treat congestive heart failure
Read More
31 Jan

BioWorld Med Tech

Biocardia wins IDE for cell therapy as treatment for angina
Read More
03 Oct

BioWorld Med Tech

Biocardia presses on with Cardiamp pivotal trial to treat patients with heart failure
Read More
26 May

Med Latest

BioCardia® Helix Results in Higher Stem Cell Retention in Myocardium
Read More

press releases

16 Sep
2019 BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned
21 Aug
2019 BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights
07 Aug
2019 BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery
06 Aug
2019 BioCardia Announces Closing of $10.0 Million Public Offering
02 Aug
2019 BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to NASDAQ
25 Jul
2019 BioCardia Signs Exclusive Development Agreement with AstraZeneca
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS